Barger SR, Reilly NS, Shutova MS, Li Q, Maiuri P, Heddleston JM, Mooseker MS, Flavell RA, Svitkina T, Oakes PW, Krendel M, Gauthier NC

Membrane-cytoskeletal crosstalk mediated by myosin-I regulates adhesion turnover during phagocytosis.

Nat Commun 2019; 1249. doi: 10.1038/s41467-019-09104-1

Hetmanski JHR, de Belly H, Busnelli I, Waring T, Nair RV, Sokleva V, Dobre O, Cameron A, Gauthier N, Lamaze C, Swift J, Del Campo A, Starborg T, Zech T, Goetz JG, Paluch EK, Schwartz JM, Caswell PT

Membrane Tension Orchestrates Rear Retraction in Matrix-Directed Cell Migration.

Dev Cell 2019; 460-475.e10. doi: 10.1016/j.devcel.2019.09.006

Monzo P, Crestani M, Chong YK, Ghisleni A, Hennig K, Li Q, Kakogiannos N, Giannotta M, Richichi C, Dini T, Dejana E, Maiuri P, Balland M, Sheetz MP, Pelicci G, Ang BT, Tang C, Gauthier NC

Adaptive mechanoproperties mediated by the formin FMN1 characterize glioblastoma fitness for invasion.

Dev Cell 2021; 2841-2855.e8. doi: 10.1016/j.devcel.2021.09.007

Vorselen D, Barger SR, Wang Y, Cai W, Theriot JA, Gauthier NC, Krendel M

Phagocytic 'teeth' and myosin-II 'jaw' power target constriction during phagocytosis.

Elife 2021; . doi: 10.7554/eLife.68627

Ghersi D, Parmar MK, Stewart LA, Marsoni S, Williams CJ

Early ovarian cancer and the icon trials.

Eur J Cancer 1992; 1297. doi: 10.1016/0959-8049(92)90497-p

Marsoni S, Torri V, Taiana A, Liberati A, Labianca R, Pancera G, Gray R, Clarke M

Efficacy of intraportal infusion for colon cancer: a fair assessment?

J Clin Oncol 1991; 888-9. doi: 10.1200/JCO.1991.9.5.888

Grilli R, Alexanian A, Apolone G, Fossati R, Marsoni S, Nicolucci A, Torri V, Zola P, Compagnucci M, Di Mambro E

The impact of cancer treatment guidelines on actual practice in Italian general hospitals: the case of ovarian cancer.

Ann Oncol 1990; 112-8. doi: 10.1093/oxfordjournals.annonc.a057687

Marsoni S, Torri V, Valsecchi MG, Belloni C, Bianchi U, Bolis G, Bonazzi C, Colombo N, Epis A, Favalli G

Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).

Br J Cancer 1990; 444-50. doi: 10.1038/bjc.1990.315

Grilli R, Alexanian AA, Apolone G, Confalonieri C, Fossati R, Liati P, Liberati MC, Marsoni S, Mosconi P, Monferroni N

Trends in patterns of care for breast cancer in Italy (1979-1987).

Tumori 1990; 184-9. doi: 10.1177/030089169007600207

Apolone G, Grilli R, Alexanian AA, Confalonieri C, Labianca R, Liati P, Marsoni S, Martignoni G, Mosconi P, Nicoluci A

Quality of care of colorectal cancer patients in general hospitals: diffusion and impact of management guidelines.

Tumori 1990; 261-9. doi: 10.1177/030089169007600311

Marsoni S, Ungerleider RS, Hurson SB, Simon RM, Hammershaimb LD

Tolerance to antineoplastic agents in children and adults.

Cancer Treat Rep 1985; 1263-9.

Erba E, Ubezio P, Pepe S, Vaghi M, Marsoni S, Torri W, Mangioni C, Landoni F, D'Incalci M

Flow cytometric analysis of DNA content in human ovarian cancers.

Br J Cancer 1989; 45-50. doi: 10.1038/bjc.1989.217

Foster BJ, Clagett-Carr K, Marsoni S, Simon R, Leyland-Jones B

Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?

Cancer Treat Rep 1986; 1003-14.

Bizzi A, Codegoni AM, Landoni F, Marelli G, Marsoni S, Spina AM, Torri W, Mangioni C

Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival.

Cancer Res 1988; 6222-6.

Weiss RB, Grillo-López AJ, Marsoni S, Posada JG, Hess F, Ross BJ

Amsacrine-associated cardiotoxicity: an analysis of 82 cases.

J Clin Oncol 1986; 918-28. doi: 10.1200/JCO.1986.4.6.918

Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R

Therapeutic response in phase I trials of antineoplastic agents.

Cancer Treat Rep 1986; 1105-15.

Marsoni S, Hoth D, Simon R, Leyland-Jones B, De Rosa M, Wittes RE

Clinical drug development: an analysis of phase II trials, 1970-1985.

Cancer Treat Rep 1987; 71-80.

Liberati A, Mangioni C, Bratina L, Carinelli G, Marsoni S, Parazzini F, Regallo M, Talamini R, Tognoni G

Process and outcome of care for patients with ovarian cancer.

Br Med J (Clin Res Ed) 1985; 1007-12. doi: 10.1136/bmj.291.6501.1007

Wittes RE, Marsoni S, Simon R, Leyland-Jones B

The phase II trial.

Cancer Treat Rep 1985; 1235-9.

Libretti A, Piazza E, Scanni A, Tomirotti M, Biraghi M, Scapaticci R, Bianchi C, Restelli G, Scarpazza G, Calzavara MP, Marsoni S, Morasca L

Bleomycin, vincristine, and methotrexate (BOM) in squamous cell carcinoma of the lung: a phase II study.

Cancer Treat Rep 1981; 171-2.

Ottolenghi I, Piazza E, Marsoni S, Trabattoni A, Natale N, Recchia M, Morasca L

Vincristine and bleomycin do not interfere with infusional plasma levels of methotrexate.

Eur J Cancer (1965) 1981; 365-6. doi: 10.1016/0014-2964(81)90129-8

Shoemaker DD, O'Dwyer PJ, Marsoni S, Plowman J, Davignon JP, Davis RD

Spiromustine: a new agent entering clinical trials.

Invest New Drugs 1983; 303-8. doi: 10.1007/BF00177413

O'Dwyer PJ, Shoemaker DD, Jayaram HN, Johns DG, Cooney DA, Marsoni S, Malspeis L, Plowman J, Davignon JP, Davis RD

Tiazofurin: a new antitumor agent.

Invest New Drugs 1984; 79-84. doi: 10.1007/BF00173791

O'Dwyer PJ, Alonso MT, Leyland-Jones B, Marsoni S

Teniposide: a review of 12 years of experience.

Cancer Treat Rep 1984; 1455-66.

Pisoni MB, Libretti A, Piazza E, Vago G, Scapaticci R, Bianchi C, Tomirotti M, Scanni A, Calzavara MP, Cassani L, Scarpazza G, Marsoni S, Morasca L

Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma.

Cancer Treat Rep 1981; 731-2.

Poster DS, Penta J, Marsoni S, Bruno S, Macdonald JS

Bis-diketopiperazine derivatives in clinical oncology: ICRF-159.

Cancer Clin Trials 1980; 315-20.

Morasca L, Marsoni S, Pisoni MB, Piazza E, Vago G, Casali W, Cogo R, Bianchi C, Scapaticci R

VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.

Cancer Chemother Pharmacol 1982; 209-10. doi: 10.1007/BF00254551

Ottolenghi L, Morasca L, Marsoni S, Piazza E, Soresi E, Libretti A, Garattini S

Plasma levels of cyclophosphamide in patients under polychemotherapeutic regimens.

Biomedicine 1980; 123-7.

Piazza E, Donelli MG, Broggini M, Sessa C, Natale N, Ottolenghi L, Marsoni S, Libretti A, Mangioni C, Morasca L

Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.

Cancer Treat Rep 1980; 845-54.

Alexanian AA, Scorpiglione N, Apolone G, Fossati R, Liberati A, Grilli R, Liberati MC, Marsoni S, Monferroni N, Mosconi P

Breast cancer surgery in 30 Italian general hospitals.

Eur J Surg Oncol 1993; 123-9.

%PLACEHOLDER%